Seletalisib (formerly known as UCB-5857) is a novel, potent, ATP-competitive, and selective, small-molecule inhibitor of PI3Kδ with an IC50 value of 12 nM.

α-Linolenic acid is a natural fatty acid extracted from seed oils with anti-arrhythmic and antithrombotic activity.

AZD6482 (KIN193) is a novel, potent, selective and ATP competitive PI3Kβ (phosphatidylinositol-3-kinase) inhibitor with potential anticancer activity.

Leniolisib (formerly CDZ173; CDZ-173; Joenja) is a novel, potent and selective PI3K (phosphatidylinositol 3-kinase inhibitor) inhibitor with immunomodulatory effects.

PKI-402 is a novel, potent, dual and pan-inhibitor of PI3K/mTOR (phosphatidylinositol 3-kinase/mammalian target of rapamycin) with potential anticancer activity.

Samotolisib (LY3023414; GTPL8918) is an orally bioactive, selective and ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.

SAR405 (SAR-405) is a novel, potent and selective PIK3C3/Vps34 inhibitor (IC50 = 1.2 nM) with anticancer activity.

Fluorofenidone(AKF-PD; AKFPD), a derivative of AMR69, a promising multifunctional antifibrosis pyridinone drug which act as a potent inhibitor of nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis.

Copanlisib (formerly BAY 80-6946; brand name: Aliqopa) is a potent, ATP-competitive and pan-class I PI3K (phosphoinositide 3-kinase) inhibitor with potential anticancer activity.

VPS34-IN2 (PIK-III; Vps34-PIK-III) is a novel, potent and selective inhibitor of VPS34 (IC50 = 18 nM) with the ability to modulate autophagy in Vivo.